Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Is trogarzo an infusion for hiv?Does Wellbutrin help with depression-related fatigue?Does dong quai regulate menstrual cycles?Is lipitor's effectiveness affected by antidepressant type?Is there a generic version of restasis?
See the DrugPatentWatch profile for Mirabegron
How long will Mirabegron's patent last? Mirabegron, an oral beta-3 adrenergic receptor agonist, is used to treat overactive bladder symptoms. The drug's patent is held by Astellas Pharma Inc. [1] According to DrugPatentWatch.com, the U.S. patent for Mirabegron (Myrbetriq) is set to expire on February 8, 2027 [2]. What are the potential biosimilar entrants in the market? Since the patent is set to expire in the coming years, it is likely that biosimilar versions of Mirabegron will enter the market, potentially challenging Astellas Pharma's market share. Biosimilar manufacturers may include [3] Teva Pharmaceuticals [4], Sun Pharma, and others. When can we expect biosimilar versions to become available? In the United States, biosimilars often enter the market 12-18 months after the reference product's patent expiration. Given the patent expiration date of February 8, 2027, it is possible that biosimilar versions of Mirabegron may become available in the United States sometime in 2028. What differences can we expect between Mirabegron and biosimilars? Biosimilars are not exact replicas of the original product but are highly similar in terms of safety, efficacy, and overall quality. In many cases, biosimilars may not have the same packaging, manufacturing process, or even brand name as the original product. Mirabegron and biosimilars may have similar formulations and dosing regimens, but the biosimilars will not have the same patent protection. Can biosimilar entry impact Astellas Pharma's revenue? Yes, the entry of biosimilars into the market can potentially impact Astellas Pharma's revenue. As the market share of the originator product decreases, the revenue generated from the sale of Mirabegron may also decline. References: [1] Astellas Pharma Inc. (2023). Myrbetriq (Mirabegron) Product Page. Retrieved 2023-12-01. [2] DrugPatentWatch.com. (2023). Mirabegron (Myrbetriq): Patent Expiration. Retrieved 2023-12-01. [3] Teva Pharmaceuticals. (2023). Teva Enters Into Collaboration Agreements for Development and Commercialization of Biosimilars. Retrieved 2023-12-01. [4] Sun Pharma. (2023). Sun Pharma Strengthens its Presence in the US Biosimilars Market. Retrieved 2023-12-01.